UK Roadmap Sets Clear Timelines to Phase Out Animal Testing

The UK Government has published its "Replacing Animals in Science" roadmap, a strategic document providing clarity on the national plan to reduce the use of animals in drug safety testing. The roadmap outlines a commitment to advancing and validating New Approach Methodologies (NAMs), recognizing them as the future standard for preclinical assessment.

The strategy champions NAMs, explicitly including Organ-on-a-Chip (OOC) systems, advanced AI analysis, and 3D bioprinted tissues, as essential for meeting stringent regulatory standards. This approach is backed by an estimated £75 million in new funding to accelerate the validation and adoption of these methods.

The roadmap sets firm targets: regulatory animal testing for skin/eye irritation is slated to end by late 2026, and non-human primate pharmacokinetic studies are targeted for substantial reduction by 2030.

Javelin Biotech: Supporting the Transition

This official regulatory pivot confirms the long-term strategic direction of Javelin Biotech. The company's Tissue Chip Platform is specifically built to generate the sophisticated mechanistic and translational data required for these complex regulatory endpoints. Javelin is committed to collaborating with global partners and regulatory bodies to ensure a successful and scientifically confident transition to this new era of predictive in vitro testing.

https://www.gov.uk/government/news/animal-testing-to-be-phased-out-faster-as-uk-unveils-roadmap-for-alternative-methods